TG Therapeutics (TGTX) Fundamentals 2026 — P/E 16.7x, Revenue Analysis | SniperIQ
TG Therapeutics (TGTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of $8.1B, trading at $53.05 on the NASDAQ. This SniperIQ fundamentals page covers TG Therapeutics's valuation (P/E 16.7x, P/B 13.1x), profitability (net margin 66.0%), revenue ($616M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is TG Therapeutics's market cap?
TG Therapeutics (TGTX) has a market capitalization of approximately $8.1B, trading at $53.05 on the NASDAQ. Market cap moves with the live share price.
What is TG Therapeutics's P/E ratio?
TG Therapeutics's trailing twelve-month P/E ratio is 16.7x, with a price-to-book (P/B) of 13.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is TG Therapeutics?
TG Therapeutics runs a net profit margin of 66.0%, a gross margin of 83.0%, and an operating margin of 21.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TG Therapeutics generate?
TG Therapeutics reported revenue of $616M for fiscal year 2025, with net income of $447M and earnings per share (EPS) of 3.1. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TG Therapeutics pay a dividend?
TG Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is TG Therapeutics financially healthy?
TG Therapeutics carries a debt-to-equity ratio of 1.29x and a current ratio of 5.81x, with a market beta of 1.60. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TG Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TG Therapeutics (TGTX) the key facts are: market cap $8.1B, P/E 16.7x, revenue $616M, 52-week range 25.28-59.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track TG Therapeutics's full fundamentals live
Get TG Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.